This has been attributed to the unexpected binding to vascular endothelial growth factor receptor 2, frizzled class receptor 5, and UL16 binding protein 2 that may correlate with the side effects of capillary hemangiomas observed in clinical studies with camrelizumab (45). Here, FZD5 is linked to capillary hemangioma.